Google
OSUR Stock Analysis — ORASURE TECHNOLOGIES INC (Healthcare >> Medical Instruments & Supplies)
OSUR FAQ
What is OSUR's ROE?
ORASURE TECHNOLOGIES INC reports a Return on Equity (ROE) of -23.96%.
What is OSUR's dividend yield?
ORASURE TECHNOLOGIES INC offers a dividend yield of 0.00%.
What is OSUR's Quality Score?
Our AI rates OSUR's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OSUR?
Our AI Timing Score for OSUR is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OSUR belong to?
ORASURE TECHNOLOGIES INC is classified under the Healthcare >> Medical Instruments & Supplies sector on the NASDAQ exchange
OSUR AI Analysis Summary
Our AI summary for OSUR: ORASURE TECHNOLOGIES INC (NASDAQ), Healthcare >> Medical Instruments & Supplies sector. The stock currently trades at a P/E of 0.00, ROE of -23.96%, a dividend yield of 0.00%. Its financial Quality Score stands at 8/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.05
Price
0.08
(2.02%)
Day Change
|
|
|---|
OSUR, the overall quality is not good ( Quality = 8) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.05 |
| PBV / Sector |
0.87 / 3.37
GREAT
|
| Earning Per Share | -1.11 |
| PE / Sector |
N/A / 44.25
|
| PEG or PE/Growth / Sector |
N/A / -1.35
|
| Average 1M Daily Value |
1.46 M
GREAT
|
| Average 1W Daily Value |
1.14 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:17 |
| Symbol | OSUR |
| Name | ORASURE TECHNOLOGIES INC |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NASDAQ |
| Listed Shares | 68.85 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 273.33 / 16,159.14 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 220 East First Street, Bethlehem, PA, United States, 18015
Phone: 610 882 1820
Website: https://www.orasure.com
Employees: 500
Description: OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Medical Instruments & SuppliesAnalysed on the same criteria, ordered by market cap